Kuwait Hospital, Central Circle Company announce successful completion of pioneering medical procedure
KUWAIT: Kuwait Hospital, in collaboration with Central Circle Company, the authorized local distributor of Abbott Vascular, announced the successful completion of a pioneering medical procedure — one of the first of its kind in Kuwait — to treat a patient suffering from Chronic Limb-Threatening Ischemia (CLTI). The procedure was led by Dr Ahmad Ameer, Consultant Vascular Surgeon, who utilized the Abbott Esprit BTK Everolimus Eluting Resorbable Scaffold System — a global innovation representing a major breakthrough in the treatment of small artery blockages below the knee.
This stent is the first fully dissolvable scaffold of its kind. It is temporarily implanted to open the blocked artery and deliver the therapeutic drug everolimus, then gradually dissolves after fulfilling its purpose — leaving no permanent metal behind. This process enhances healing potential and reduces the risk of restenosis or the need for future interventions. Dr Ahmad Ameer, Consultant Vascular Surgeon at Kuwait Hospital, said: “This procedure marks a new phase in vascular care in Kuwait. It provides an effective solution for complex below-the-knee occlusions and delivers superior outcomes compared to traditional treatments.”
Dr Ziad Al-Alyan, CEO of Central Circle Company, stated: “Introducing this innovative technology into Kuwait’s healthcare system reflects our ongoing commitment to bringing the latest medical solutions from Abbott, with the goal of enhancing healthcare quality and improving patients’ lives.” This medical achievement exemplifies the fruitful collaboration between Kuwait Hospital, Central Circle and Abbott, reinforcing Kuwait’s position as a regional leader in adopting cutting-edge medical technologies to serve patients.
